Source:http://linkedlifedata.com/resource/pubmed/id/10618688
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2000-2-4
|
| pubmed:abstractText |
Since the introduction of multimodality treatment, the prognosis of patients with high-grade non-metastatic osteosarcoma has significantly improved. A retrospective review was performed to assess the long-term results of this approach in a single centre setting, and to investigate the impact of potential clinical prognostic factors. Between 1985 and 1993, 35 patients with stage II-A and II-B osteosarcoma underwent preoperative chemotherapy (high-dose methotrexate), wide surgery, and adjuvant chemotherapy (cisplatin-doxorubicin/bleo-mycin-cyclophosphamide-dactinomycin) (modified T-10A protocol). There were 19 males and 16 females. Median patient age was 17 y (range 12-42). Primary tumour sites were the extremities (83%) and axial bones (17%). In spite of an unfavourable grade 3-4 histologic response rate to high-dose methotrexate of 12%, 31 (88%) patients were able to undergo limb-sparing surgery and 28 (80%) were rendered disease free after the planned therapy. Median follow-up was 8 y. The actuarial overall survival and disease-free survival rates were 64% and 49% at 5 y, and 59% and 49% at 10 y, respectively. Tumour size and primary site were significant prognostic factors for survival in univariate analyses. In conclusion, long-term survival after combined modality treatment can be achieved in more than 60% of patients with localised osteosarcoma, including non-appendicular lesions. Limb-sparing surgery is a realistic goal for most cases. The prognostic value of tumour necrosis and the efficacy of neoadjuvant chemotherapy should be interpreted according to individual high-dose methotrexate scheduling.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1357-0560
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
255-60
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:10618688-Adolescent,
pubmed-meshheading:10618688-Adult,
pubmed-meshheading:10618688-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10618688-Bone Neoplasms,
pubmed-meshheading:10618688-Chemotherapy, Adjuvant,
pubmed-meshheading:10618688-Child,
pubmed-meshheading:10618688-Drug Administration Schedule,
pubmed-meshheading:10618688-Female,
pubmed-meshheading:10618688-Follow-Up Studies,
pubmed-meshheading:10618688-Humans,
pubmed-meshheading:10618688-Male,
pubmed-meshheading:10618688-Methotrexate,
pubmed-meshheading:10618688-Neoadjuvant Therapy,
pubmed-meshheading:10618688-Neoplasm Staging,
pubmed-meshheading:10618688-Osteosarcoma,
pubmed-meshheading:10618688-Prognosis,
pubmed-meshheading:10618688-Retrospective Studies,
pubmed-meshheading:10618688-Treatment Outcome
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Long-term results after combined modality treatment for non-metastatic osteosarcoma.
|
| pubmed:affiliation |
Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain. japaricio@ene.es
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|